|Dr. Mark A. Goldsmith M.D., Ph.D.||CEO, Pres & Chairman||506.3k||N/A||1962|
|Ms. Margaret A. Horn||COO & Gen. Counsel||386.38k||N/A||1963|
|Dr. Stephen M. Kelsey M.D., FRCP, FRC Path.||Pres of R&D||426.35k||N/A||1961|
|Dr. Martin D. Burke||Co-Founder & Chairman of Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Michael A. Fischbach||Academic Co-Founder & Member of Scientific Advisory Board||N/A||N/A||1981|
|Dr. Kevan M. Shokat||Academic Co-Founder & Member of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. Jack Anders||VP of Fin. & Principal Accounting Officer||N/A||N/A||1977|
|Mr. David L. Pompliano||Founding Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Walter Reiher Ph.D.||Chief Information Officer||N/A||N/A||N/A|
|Ms. Luan M. Wilfong||Sr. VP of HR||N/A||N/A||N/A|
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit targets primarily within the RAS and mTOR signaling pathways. The company's principal product candidate is RMC-4630, an inhibitor of SHP2, which is in Phase 1b/2 study for the treatment of RAS-dependent tumors. Its products in preclinical stage include mutant RAS proteins; SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a mTORC1 inhibitor. Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors. The company was founded in 2014 and is headquartered in Redwood City, California.
Revolution Medicines, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.